Exemestane Versus Tamoxifen
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
CANCER DE MAMA
Oncology Tribune January 2013 HK
1 Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive.
These slides were released by the speaker for internal use by Novartis
A Report from SABCS Up-to-Date Review of the Treatment of Early Breast Cancer
Screening Mammography Value vs. Jeopardy
Objectives
Endocrine therapy in breast cancer
A recent survey showed that only 10% of physicians thought they had the necessary training and knowledge in genomics to use genetic testing in treating.
1 Study Of Letrozole Extension IBCSG 35-07/BIG 1-07 S LE.
